TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04560335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach to FIt
Description: CoachToFit: Those randomized to CoachToFit will have the CoachToFit app downloaded to their phone by the peer coach and will work with the coach to initialize the app. Individuals will receive an activity tracker compatible with Android OS and iOS (Amazfit Bit) and a Bluetooth scale (Smart Body scale). Participants will be instructed by the peer to complete at least two CoachToFit modules per week. Modules take about~15 minutes to complete and have embedded knowledge quizzes and end with a choice of three goals to practice over the next week. They will also set up a time for the first 20-minute coaching call, which will then continue weekly.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Veterans randomized to the treatment as usual arm will continue to access all services of the VA Pittsburgh, and will participate in three research interviews. After the first meeting, all participants will meet with a peer coach (peer specialists) who will discuss with them the importance of losing weight (using a structured conversation that follows a handout which is provided to the participant). The handout was developed with input from a VA dietitian as well as Veterans and is graphically appealing, with a simple layout, and provides information on diet and activity as well as the local MOVE! schedule
Study: NCT05148273

Intervention type: BEHAVIORAL
Intervention: telenursing
Description: 7-24 counseling and daily treatment protocol reminders will be given to the intervention group.
Study: NCT05824520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITS plus OMT
Description: Invasive treatment strategy plus optimal medical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OMT
Description: Optimal medical therapy alone
Study: NCT05467943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
Study: NCT06162572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095018
Description: Via IV infusion on Day 1 of each 21-day cycle
Study: NCT05282940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon CD
Description: Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug
Study: NCT06489964

Intervention type: OTHER
Group type: OTHER
Intervention: Transitional Stepped Co-payment Model - Step 1
Description: Step 1 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 25% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.

Intervention type: OTHER
Group type: OTHER
Intervention: Transitional Stepped Co-payment Model - Step 2
Description: Step 2 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 50% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.

Intervention type: OTHER
Group type: OTHER
Intervention: Transitional Stepped Co-payment Model - Step 3
Description: Step 3 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 75% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.

Intervention type: OTHER
Group type: OTHER
Intervention: Transitional Stepped Co-payment Model - Step 4
Description: Step 4 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 100% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
Study: NCT06162572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095024
Description: Via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095029
Description: Via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095018 Recommended Dose Expansion (RDE)
Description: Via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095024 RDE
Description: Via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095029 RDE
Description: Via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cemiplimab
Description: 350 mg via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg via IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg via IV infusion on Day 1 of each 21-day cycle
Study: NCT06350318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib is an anti-cancer medication administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib is an anti-cancer medication administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a biologic medication administered intravenously or subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a biologic medication administered intravenously or subcutaneously.
Study: NCT06641791

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiotherapy (SRT)
Description: 2400 cGy in 3 fractions - day 0/7/21, OR, 2500 cGy in 5 fractions over 1 week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: 4500 cGy in 5 fractions (twice a week to primary and nodal GTV, OR, 4000 cGy in 5 fractions twice a week if organs at risk.
Study: NCT04698330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine placebo tablets
Description: 0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Berberine placebo tablets
Description: 0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin placebo tablets
Description: 0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inulin placebo tablets
Description: 0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
Study: NCT05537129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Gastrectomy
Description: The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Gastrectomy
Description: The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
Study: NCT05283850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Calcium, Low Sodium (HCLS) Crystalloid Therapy
Description: Half-normal saline IV drip and 1g IV bolus Calcium Chloride.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Calcium, High Sodium (HCHS) Crystalloid Therapy
Description: Normal saline IV drip and 1g IV bolus Calcium Chloride.
Study: NCT03951467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.
Description: Three interviews between the patient and a health advisor trained for the study: two times before discharge from hospital and a telephone reminder within 3 weeks after discharge.~First and second interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: within 3 weeks after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations.~Two interviews by phone with a clinical reseach assistant at 30 days et 90 days after discharge which consist of questionnaire.
Study: NCT06229509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effective noninvasive ventilation
Description: Noninvasive ventilation set to alleviate dyspnea Inspiratory aid set according to a preliminary test (aiming for a diminution of 2 points in Borg score)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham noninvasive ventilation
Description: Noninvasive ventilation set with an insufficient inspiratory aid to alleviate dyspnea
Study: NCT05195710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y-90) resin microspheres
Description: Given by scan
Study: NCT05707650

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reverse breech extraction technique or push technique
Description: using reverse breech extraction technique or push technique for disimpaction of fetal head during cs of a fully dilated cervix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reverse breech extraction technique or push technique
Description: using reverse breech extraction technique or push technique for disimpaction of fetal head during cs of a fully dilated cervix
Study: NCT04808687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel and S-1
Description: Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area \< 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 \< 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
Study: NCT05288088

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: This is an observational study
Study: NCT05330520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Butterfly Medical Prostatic Retraction Device (the Butterfly device) removal/replacement
Description: when necessary, the device may be removed or replaced easily through the urethra due to its minimal surface and easy release from the mucosa covering it.
Study: NCT05382481

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peak value anti-Xa
Description: This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the peak level of anti-Xa after 4 to 6 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the peak value of anti Xa.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trough value anti-Xa
Description: This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the trough level of anti-Xa after 12 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the trough value of anti Xa.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: This group will receive fixed dose of low molecular weight heparins (LMWH) 40mg, once a day. And will not detect the level of anti-Xa
Study: NCT05153382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy
Description: DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly meetings and individual therapy conducted in 60 minute biweekly sessions. Family participation in skills training is highly encouraged. Skills training proceeds as follows: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants by cell phone for in-vivo skills coaching between sessions.
Study: NCT05614011

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-PCR Test
Description: High sensitivity RT-PCR COVID-19 Test. A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's Instructions For Use (IFU) in one nostril.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Real-time PCR Test
Description: Mid-turbinate nasal swab samples will be taken from the opposite nostril that was not swabbed for the comparator sample using Copan FLOQ swabs and placed into MSwab buffer. In instances where opposite nostrils cannot be swabbed for both the comparator and the candidate tests, a 15-minute waiting period to allow for viral reloading will occur before collecting the candidate test sample.
Study: NCT05332574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB263T
Description: Participants will receive IV infusions of GB263T at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive GB263T at predefined dose levels and frequency, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days.
Study: NCT06007612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Context Sensitivity in Emotion Regulation
Description: Context Sensitivity of affective intensities and its association to Emotion Regulation Flexibility Selection
Study: NCT05742620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib+CAPEOX/SOX
Description: Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1.
Study: NCT05749588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: SHR-A1811
Description: A1: an anti-HER2 antibody-drug conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A2: SHR-A1811 with Camrelizumab
Description: A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody
Study: NCT06293586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peribulbar block
Description: Peribulbar block using a two-injection technique was performed by a second anesthetist under sterile conditions and before the application of surgical drapes. LAM was injected both infratemporal and superonasally using a 26-G needle, in contrast to the single infratemporal injection approach.~Gentle digital oculopression was performed for 5 minutes
Study: NCT06287463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3084
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3084
Description: Administered orally
Study: NCT05749588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1: TROP2 ADC
Description: B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B2: TROP2 ADC with Camrelizumab
Description: B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~Camrelizumab: an anti-programmed death-1 (PD-1) antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1: SHR-A1811
Description: C1: an anti-HER2 antibody-drug conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2: SHR-A1811 with BP102
Description: C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1: TROP2 ADC
Description: D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2: TROP2 ADC with BP102
Description: D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1: SHR-A1811
Description: E1: an anti-HER2 antibody-drug conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F1: TROP2 ADC
Description: F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
Study: NCT06293586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sub-tenon block
Description: Children in the sub-Tenon group received a sub-Tenon block. Sub-Tenon's anesthesia was performed with 0.5% bupivacaine (0.08 ml/kg), bearing in mind not to exceed the maximum dose. Under sterile conditions, a 19- gauge curved blunt metallic cannula (25 mm) was inserted into sub-Tenon's space and the local anesthetic was injected by the ophthalmologist after the application of surgical drapes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Children in the control group received IV paracetamol (15 mg/kg) after induction of anesthesia before any surgical intervention.
Study: NCT05824481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Capsule
Study: NCT04673721

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified eggs
Description: Average 12 eggs consumed per week

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified eggs
Description: Average 12 eggs consumed per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent fasting
Description: 16-hour fast and then an 8-hour nutritional window with aim for energy needs to be consumed during an 8 hour eating window (e.g., 11 am - 7 pm) with fasting for 16 hours (e.g., 7 pm - 11 am the next day).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent fasting
Description: 16-hour fast and then an 8-hour nutritional window with aim for energy needs to be consumed during an 8 hour eating window (e.g., 11 am - 7 pm) with fasting for 16 hours (e.g., 7 pm - 11 am the next day).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-egg supplemented
Description: 2 or less eggs consumed per week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-egg supplemented
Description: 2 or less eggs consumed per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care diet
Description: Consistency with current diet without consideration of intermittent fasting

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care diet
Description: Consistency with current diet without consideration of intermittent fasting
Study: NCT06385236

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab, an interleukin-4 receptor treatment, will be administered through a subcutaneous injection, the initial dose of 600 mg will be administered at two different injection sites (300 mg per injection), followed by a single dose of 300 mg administered every other week (Q2W).~Participants may self-administer injection after proper training.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: Benralizumab, an interleukin-5 receptor treatment, will be administered through a subcutaneous injection every 4 weeks (Q4W).~Participants may self-administer injection after proper training.
Study: NCT06558851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity endurance training
Description: 12 weeks of high intensity endurance training three times a week. Two of the weekly sessions are supervised.
Study: NCT06558929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Participants will redesign their daily routine (particularly the sleep-wake rhythm) with support from occupational therapists and an online health management platform.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Treatment
Description: Participants will receive conventional treatment and education on sleep hygiene.